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Short Communication

Acquired Hemophilia A: A possibly fatal complication of
SARS-COV-2 infection
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a
b

Dow University of Health Sciences, Karachi, Pakistan
Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan

Acquired Hemophilia A (AHA), also known as Acquired Factor VIII
deficiency, is a bleeding disorder caused by autoantibody generation
against coagulation Factor VIII (FVIII), leading to inhibition of its procoagulative effects and causing severe bleeding [1,2]. AHA is a rare
disorder, having an incidence rate of 1.5 in 1 million per annum [3].
Previous data regarding AHA have suggested half of AHA cases to be
idiopathic, however the other half has been associated with a plethora of
factors; including infections, auto-immune diseases, pregnancy, malig
nant diseases and certain cancers [1,4] AHA usually manifests with
mucocutaneous and soft tissue bleeds, resulting in hematomas, epistaxis,
ecchymosis and gross hematuria [5]. With multiple incidences of AHA
being reported following severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) or after coronavirus disease 2019 (COVID-19) vacci
nation [4,6,7]- and a four-fold increase in AHA incidence compared to
the historical rate – it becomes important to contemplate upon an as
sociation between COVID-19 and AHA [8].
In the recent past, multiple studies have presented cases of AHA after
COVID-19 infection. Guerra et al. reported a case of 74-year-old women
who presented with gross hematuria, due to right ureteral orifice bleed,
four weeks after recovering from COVID-19 infection [9]. A similar case
was reported Nardella et al. of spontaneous developments of ecchymosis
bilaterally in the deltoid region, which was followed by further subcu
taneous hematomas in the lower limbs. These hematomas also devel
oped few weeks after resolution of Covid-19 symptoms [10]. This
association was further emphasized by Wang et al., whom reported
hematomas and diminished sensations in the right upper limb, with
further bleeds from intravenous catheters in an asymptomatic Covid-19
patient [6]. Moreover, a delayed case of AHA was reported in a 73-year
old man by Hafzah et al., who developed a large ecchymosis on his left
thigh, four months after getting infected with the Covid-19 virus [7]. An
interesting case of AHA re-exposure was also reported of a 66-year-old
man, who developed severe cutaneous and muscle bleeds following
Covid-19 infection. The patient was initially diagnosed with AHA about

a decade ago, and had been successfully treated, however the Covid
infection triggered the re-appearance of AHA [4].
Moving further, a possible co-relation between AHA and mRNA
corona-virus vaccines have also been observed lately. Leone et al. re
ported four incidences of AHA in the Italian population after adminis
tration of Pfizer-BioNTech mRNA Covid-19 vaccine [11]. Al Hennawi
et al. also reported cutaneous hematomas on multiple sites in a 75-year
old male after the administration of the second dose of the same vaccine
[12]. A similar case was also reported by Radwi et al., with presentation
of hematomas after both doses of Pfizer-BioNTech Covid vaccine in a
69-year old male [13]. Adding on, multiple cases of AHA have also been
reported after inoculation with the Moderna Covid-19 mRNA vaccine.
Cittone et al. reported three cases of AHA in the Swiss population [8]
Moreover, Fu et al. also presented a case of a 77-year-old male with
multiple ecchymoses bilaterally on the forearms and legs, with further
papules and hemorrhagic blisters on the patient’s back and hands three
weeks after the second dose of the Moderna vaccine [14].
SARS-COV-2 infection has been associated with several hematolog
ical issues - including development of lupus anti-coagulants and autoimmune hemolytic anemia – with AHA being one of the disorders. The
exact etiology for this association remains vague, however it has been
postulated that specific patients in the convalescent phase of the Covid19 infection might develop an antibody response that cross reacts with
the pre-existing antigenic determinants of coagulation factors and/or
the red blood cell membrane [15]. Adding on, AHA presentation
following Covid-19 vaccination might be due to a couple of factors. It is
hypothesized that the vaccine might produce a non-specific activation of
autoreactive B and T cells, leading to AHA [13].Furthermore, antigenic
mimicry might also result in the association [13].Therefore, the afore
mentioned mechanisms could be the possible pathophysiology of AHA
in Covid-19 patients.
In conclusion, although SARS-COV-2 mostly affects the respiratory
tract, clinicians must also be aware of other less reported outcomes
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involving other organs. Here we have highlighted the possible associa
tion of AHA, a possible fatal complication, in COVID-19 patients.
Because of AHA’s life threatening nature, it should always be considered
in differential diagnosis in COVID-19 patients with normal platelet
levels presenting with bleeding. Moving forward, studies need to be
conducted to better understand the causative relationship between
SARS-COV-2 and the potentially fatal disease AHA.
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